Journal of Clinical and Cellular Immunology
Open Access
ISSN: 2155-9899
ISSN: 2155-9899
Ljudmila Stojanovich
Bezhanijska Kosa University Medical Center, Serbia
Keynote: J Clin Cell Immunol
Antiphospholipid syndrome (APS) or Hughes syndrome is probably the most important paradigm of systemic autoimmune disease. Although at present APS is a well-described, difficult-to-diagnose entity, it took many decades to define the diagnostic criteria. Early diagnosis is critical in avoiding major organ damage. However, the lack of a gold standard test to confirm diagnosis often results in delays or misdiagnosis. Following the application of the Sapporo criteria, controversy arose because those criteria identify a more homogeneous group of APS patients at the expense of excluding another, a group collectively referred to as seronegative APS. The latest classification criteria for diagnosing APS are the 2006 reviewed Sapporo criteria that require the presence of at least one clinical manifestation and one positive laboratory criteria. Following the application of the Sapporo criteria, controversy arose because those criteria identify a more homogeneous group of APS patients at the expense of excluding another, a group collectively referred to as seronegative APS. The need for more guidelines regarding the detection of LA is now fulfilled by the SSC updated guidelines. There are recent studies present on the most promising antibodies of this heterogeneous aPL family. Nowadays, APS is increasingly recognized as a multisystem disease, the clinical expression of which may include (many non-criteria) cardiac, neurological, hematological, cutaneous and other manifestations. There is a transition from APS to SLE with secondary APS (sAPS). Special attention should be given to secondary APS patients when they are submitted to high-risk events: from 7-10% patients with PAPS may go on to develop SLE. Despite updates of the diagnostic criteria, the diagnosis of SLE and APS remains difficult.
Ljudmila Stojanovich received her PhD in Medicine, with the thesis “Neuropsychiatric manifestations in patients with Systemic Lupus Erythematosus” in 1999. She is the scientific director in the Bezhanijska Kosa, University Medical Center of Belgrade University, where she is currently a Full Research Professor. Her research focuses on Systemic Lupus Erythematosus, Antiphospholipid Syndrome, and Vaccination in patients with Autoimmune Rheumatic Diseases. She is an author of three monographs and of about 250 articles on various aspects of Autoimmune Rheumatic disorders, published in international and domestic journals and in conference proceedings. She is in Editorial Boards (Editorial Boards Lupus (LONDON). /Reviewer in the “CURRENT CONTENTS” or “Science citation index”, like Lupus Reviewer Database, Cellular, and Molecular Neurobiology, The Journal of Vaccine jvac@elsevier.com, The Journal of Rheumatology, Allergologia et Immunopathologia and others. She is a member of number International Project, like of “the European Forum on Antiphospholipid Antibodies”, “Multicenter studies antiphospholipid antibodies, infections, and autoimmune diseases”. She is a mentor/Supervisor ships a number of post-doc students. She was an Invited Speaker for many lectures in Congresses and Symposia; organizer and Chairman of many Workshops, Seminars and Symposia; the member of the Steering Committee of the “(EULAR) recommendations for vaccination in patients with auto-immune inflammatory rheumatic diseases (AIIRD)”, and EULAR Honorary Member; chairman in the International Congress “Antiphospholipid syndrome (Hughes syndrome) importance of multidisciplinary approaches- 30 years since definition”, 2013, “GRANT 2015” of the EUROPEAN STROKE CONFERENCE » for “excellent research in cerebrovascular diseases reviewed by the Scientific and programmer Committees”, and presented at the 24th Annual Meeting; Vienna, may, 2015. Member of ILLUMINATE steering committee: the phase 3 lupus ILLUMINATES clinical trials of Tabalumab/ Eli Lilly and Company, MD, PhD, FRCP, are willing to serve as a consultant to Lilly Research Laboratories, a division of Eli Lilly and Company (“Lilly”), in connection with the development of Tabalumab also known as LY2439821. Co-Chairman and the lector “LUPUS ACADEMY EASTERN EUROPEAN ROADSHOW of EULAR«: Belgrade, 18th March 2016, www.lupus-academy.org. Member of the American Association for the Advancement of Science (AAAS) from 2017; The Member of the international team of medical experts for the topic on APS (Hughes Sy). Professor Ljudmila Stojanovich’ Impact Point is 300.14, and a number of citations are 1,998.
E-mail: Ljudmila_Stojanovich@yahoo.com